Efficacy of PARP Inhibitor, Platinum, and Immunotherapy in BRCA-Mutated HER2-Negative Breast Cancer Patients: A Systematic Review and Network Meta-Analysis

The optimal treatment regimen for breast cancer patients with gBRCA mutations remains controversial given the availability of numerous options, such as platinum-based agents, polymerase inhibitors (PARPis), and other agents. We included phase II or III RCTs and estimated the HR with 95% CI for OS, P...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Wanyi, Wu, Yun, Ma, Fei, Fan, Jinhu, Qiao, Youlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966507/
https://www.ncbi.nlm.nih.gov/pubmed/36836123
http://dx.doi.org/10.3390/jcm12041588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966507/
https://www.ncbi.nlm.nih.gov/pubmed/36836123
http://dx.doi.org/10.3390/jcm12041588

Ejemplares similares